Touchlight Genetics Ltd.
- Hampton, United Kingdom
Touchlight has developed the enzymatic means of DNA amplification that resolves the significant issues with plasmid DNA fermentation that currently constrain the commercialisation of DNA based therapeutics.
Touchlight’s enzymatic DNA amplification platform is proven to address every major limitation of plasmid DNA. Touchlight’s platform is high-yielding, high-fidelity, eliminates antibiotic resistance and is capable of multi gram-scale amplification of unstable sequences (e.g. secondary structure, homopolymers) using an inexpensive benchtop process lasting less than 2 weeks.
Touchlight has exploited the unique properties of its platform to develop differentiated therapeutic applications within AAV, lentivirus, mRNA, CRISPR and DNA vaccines, as well as non-therapeutic applications in the DNA nanomaterials field.
- Sector: Medical technology
Morelands & Riverdale Buildings
Lower Sunbury Road
Hampton, TW12 2ER
United KingdomVisit website
SynbiCITE leads UKTI trade mission to SynBioBeta San Francisco 2015
SynbiCITE, along with 12 of the UK's leading synthetic biology companies, is headed to San Francisco, USA, to promote the UK synthetic biology industr...
SynbiCITE sponsors new award for synthetic biology
The winner is Oxitec and the award was announced last night, Thursday 1st October at the Ashmolean Museum in Oxford. Oxitec won the award for developi...